Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis.
Urinary colics from calculosis are frequent and intense forms of pain whose current pharmacological treatment remains unsatisfactory. New and more effective drugs are needed to control symptoms and improve stone expulsion. Recent evidence suggested that the Nitric Oxide (NO) / cyclic guanosine monophosphate (cGMP)/phosphodiesterase type 5 (PDE5) system may contribute to ureteral motility influencing stone expulsion. We investigated if PDE5 inhibitors and sGC stimulators influence ureteral contractility, pain behaviour and stone expulsion in a rat model of ureteral calculosis. We investigated: a) the sex-specific PDE5 distribution in the rat ureter; b) the functional in vitro effects of vardenafil and sildenafil (PDE5 inhibitors) and BAY41-2272 (sGC stimulator) on induced ureteral contractility in rats and c) the in vivo effectiveness of vardenafil and BAY41-2272, alone and combined with ketoprofen, vs hyoscine-N-butylbromide alone or combined with ketoprofen, on behavioural pain indicators and stone expulsion in rats with artificial calculosis in one ureter. PDE5 was abundantly expressed in male and female rats' ureter. In vitro, both vardenafil and BAY41-2272 significantly relaxed pre-contracted ureteral strips. In vivo, all compounds significantly reduced number and global duration of "ureteral crises" and post-stone lumbar muscle hyperalgesia in calculosis rats. The highest level of reduction of the pain behaviour was observed with BAY41-2272 among all spasmolytics administered alone, and with the combination of ketoprofen with BAY41-2272. The percentage of stone expulsion was maximal in the ketoprofen+BAY41-2272 group. The NO/cGMP/PDE5 pathway is involved in the regulation of ureteral contractility and pain behaviour in urinary calculosis. PDE5 inhibitors and sGC stimulators could become a potent new option for treatment of urinary colic pain.
Bayer Health Care AG - Global Drug Discovery, Department of Cardiology - Pharma Research Center Wuppertal, Wuppertal, Germany; Institute of Pharmacology, Hannover Medical School, Hannover, Germany.
Peter
P
Sandner
Bayer Health Care AG - Global Drug Discovery, Department of Cardiology - Pharma Research Center Wuppertal, Wuppertal, Germany.
Hanna
H
Tinel
Pathophysiology of Pain Laboratory, Ce.S.I., "G. D'Annunzio" University of Chieti, Chieti, Italy; Department of Medicine and Science of Aging, "G. D'Annunzio" University of Chieti, Chieti, Italy.
Giannapia
G
Affaitati
Institute of Surgical Pathology, "G. D'Annunzio" University of Chieti, Chieti, Italy.
Raffaele
R
Costantini
Pathophysiology of Pain Laboratory, Ce.S.I., "G. D'Annunzio" University of Chieti, Chieti, Italy; Department of Medicine and Science of Aging, "G. D'Annunzio" University of Chieti, Chieti, Italy.
Maria Adele
MA
Giamberardino
D000818:Animals; D001344:Autopsy; D001522:Behavior, Animal; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000737:chemistry / Q000378:metabolism*; D004195:Disease Models, Animal; D020536:Enzyme Activators / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling; D006162:Guanylate Cyclase / Q000235:genetics / Q000378:metabolism*; D020347:Lithiasis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D010146:Pain; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D014513:Ureter / Q000187:drug effects; D014514:Ureteral Calculi / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology
D020536:Enzyme Activators; D058986:Phosphodiesterase 5 Inhibitors; D012333:RNA, Messenger; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006162:Guanylate Cyclase